CeriBell (NASDAQ:CBLL) Receives Sell (E+) Rating from Weiss Ratings

Key Points

• CeriBell (NASDAQ:CBLL) has received a "sell (e+)" rating from Weiss Ratings, while Raymond James Financial recently initiated coverage with a "strong-buy" rating and a price target of $19.00.
• The stock is currently trading at $12.89, showing a slight decline of 0.4% and has a twelve-month trading range between $10.01 and $32.75.
• CeriBell posted a quarterly earnings report with an EPS of ($0.38), beating estimates, and had revenue of $21.20 million, exceeding projections.

CeriBell (NASDAQ:CBLL - Get Free Report)'s stock had its "sell (e+)" rating reiterated by equities researchers at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

Separately, Raymond James Financial started coverage on shares of CeriBell in a research note on Tuesday. They issued a "strong-buy" rating and a $19.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CeriBell has a consensus rating of "Moderate Buy" and an average price target of $30.50.

CeriBell Trading Down 0.4%

Shares of NASDAQ:CBLL traded down $0.05 during mid-day trading on Friday, reaching $12.89. The stock had a trading volume of 197,215 shares, compared to its average volume of 259,022. The firm has a 50 day simple moving average of $12.06 and a two-hundred day simple moving average of $14.82. The firm has a market cap of $472.55 million and a PE ratio of -4.31. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75. The company has a current ratio of 13.31, a quick ratio of 12.91 and a debt-to-equity ratio of 0.11.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. The business had revenue of $21.20 million for the quarter, compared to analysts' expectations of $20.52 million. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. CeriBell has set its FY 2025 guidance at EPS. On average, research analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CTO Raymond Woo sold 11,112 shares of the company's stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $12.54, for a total transaction of $139,344.48. Following the completion of the sale, the chief technology officer owned 167,704 shares of the company's stock, valued at $2,103,008.16. This represents a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 20.10% of the stock is currently owned by company insiders.

Institutional Trading of CeriBell

Several large investors have recently made changes to their positions in CBLL. KLP Kapitalforvaltning AS bought a new stake in CeriBell during the first quarter worth $36,000. Tower Research Capital LLC TRC boosted its stake in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock valued at $43,000 after purchasing an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock worth $48,000 after purchasing an additional 1,256 shares in the last quarter. New York State Common Retirement Fund bought a new position in CeriBell in the 1st quarter valued at approximately $67,000. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of CeriBell by 161.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company's stock worth $106,000 after buying an additional 3,502 shares during the last quarter.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.